中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 9
Sep.  2011
Turn off MathJax
Article Contents

Effect of fenofibrate on serum biochemical indicators and hepatic pathology in rats after bile duct ligation

  • Published Date: 2011-09-20
  • Objective To investigate the effect of Fenofibrate on serum hepatic biochemical indicators、MDA (malonaldehyde) and hepatic pathology in rats after bile duct ligation.Methods Rats were subjected to bile duct ligation to establish the cholestasis model.Twenty-four male Wistar rats were randomly divided into two groups equally: A = bile duct ligation+normal saline (BDL + NS) , B= BDL + fenofibrate (30 mg/kg daily) .All rats were sacrificed on 7th day after obtaining blood samples and liver tissue.Serum hepatic biochemical indicators were detected with automatic biochemistry analyzer;MDA assays were performed by spectrophotometer;Histopathological changes in liver was dyed with HE and observed under light microscope.Results There was no significant difference in terms of serum hepatic biochemical levels between group A and group B;The levels of MDA in rats of group B were significantly lower than in group A (P=0.001<0.05) ;The number of liver necrotic area in rats of group B was significantly smaller than in group A (P<0.05) , The number of biliary canals in rats of group B was significantly smaller than in group A (P<0.05) .Conclusion Fenofibrate administration attenuates the levels of MDA, reduces liver necrotic area and ductular proliferation.

     

  • loading
  • [1]许海波, 巩鹏.PPARs在梗阻性黄疸肝脏损伤中的作用[J].国际外科学杂志, 2007, 34 (7) , 461-465.
    [2]Cindoruk M, Kerem M, Karakan T, et al.Peroxisome prolif-erators-activated alphaagonist treatment ameliorates hepat-ic damage in rats with obstructive jaundice:an experimentalstudy[J].BMC Gastroenterology, 2007, 7 (44) :1-7.
    [3]Lalloyer F, Staels B.Fibrates, glitazones, and peroxisomeproliferator-activated receptors[J].Arterioscler ThrombVasc Biol, 2010, 30 (5) :894-899.
    [4]Post SM, Duez H, Gervois PP, et al.Fibrates suppress bileacid synthesis viaperoxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol27-hydroxylase expression[J].Arte-rioscler Thromb Vasc Biol, 2001, 21 (11) :1840-1845.
    [5]Zollner G, Trauner M.Nuclear receptors as therapeutic tar-gets in cholestatic liver diseases[J].Br J Pharmacol, 2009, 156 (1) :7-27.
    [6]Trauner M, Meierer PJ, Boyer JL.Molecular pathogenesisof cholestasis[J].New Eng J Med, 1998, 339 (17) :1217-1227.
    [7]Aller MA, Arias JL, Prieto I, et al.Bile duct ligation:step-by-step to cholangiocyte inflammatory tumorigenesis[J].Eur J Gastroenterol Hepatol, 2010, 22 (6) :651-661.
    [8]Reddy JK, Hashimoto T.Peroxisomal beta-oxidation andperoxisome proliferator-activated receptor alpha:an adap-tive metabolic system[J].Annu Rev Nutr, 2001, 21:193-230.
    [9]Qi C, Zhu Y, Reddy JK.Peroxisome proliferator-activatedreceptors, coactivators, and downstream targets[J].CellBio-chem Biophys, 2000, 32:187-204.
    [10]Bulhak AA, Jung C, Ostenson CG, et al.PPAR-alpha acti-vation protects the type 2 diabetic myocardium against ische-mia-reperfusion injury:involvement of the PI3-Kinase/Aktand NO pathway[J].Am J Physiol Heart Circ Physiol, 2009, 296 (3) :H719-H727.
    [11]Collino M, Aragno M, Mastrocola R, et al.Oxidative stressand inflammatory response evoked by transient cerebral is-chemia reperfusion:effects of the PPAR-alpha agonistWY14643[J].Free Radic Biol Med, 2006, 41 (4) :579-589.
    [12]曲艳萍, 张文锐.浅谈非诺贝特的副作用[J].中外医疗, 2010, 2 (29) :176-176.
    [13]Kobayashi A, Suzuki Y, Kuno H, et al.Effects of fenofibrateon plasma and hepatic transaminase activities and hepatictransaminase gene expression in rats[J].J Toxicol Sci, 2009, 34 (4) :377-387.
    [14]Tomkiewicz C, Muzeau F, Edgar AD, et al.Opposite regula-tion of the rat and human cytosolic aspartate aminotrans-ferase genes by fibrates[J].Biochem Pharmacol, 2004, 67 (2) :213-225.
    [15]尹蓉, 王沁, 富翠芹.姜黄素对酒精诱导的大鼠脂质过氧化反应的影响[J].世界华人消化杂志, 2008, 16 (13) :1383-1387.
    [16]Tolman KG.Defining patient risks from expanded preventivetherapies[J].Am J Cardiol, 2000, 85 (12A) :15E-19E.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2613) PDF downloads(621) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return